An anonymous director reports

ZYUS LIFE SCIENCES ANNOUNCES FILING OF AMENDED AND RESTATED LIFE OFFERING DOCUMENT

Zyus Life Sciences Corp. has filed an amended and restated offering document dated Feb. 9, 2026, with respect to the offering pursuant to and in accordance with the listed issuer financing exemption from the prospectus requirement available under Section 5A.2 of National Instrument 45-106 -- Prospectus Exemptions, as amended by Coordinated Blanket Order 45-935 -- Exemptions from Certain Conditions of the Listed Issuer Financing Exemption, previously announced on Jan. 12, 2026, and offering of the units under the LIFE offering has recommenced.

The amended and restated offering document can be accessed under the company's profile on SEDAR+ and on the company's website. Prospective investors should read the amended and restated offering document before making an investment decision. Copies of the amended and restated offering document may also be obtained from Canaccord Genuity Corp., the lead agent and sole bookrunner of the LIFE offering, at ECM@cgf.com.

About Zyus Life Sciences Corp.

Zyus (TSX Venture Exchange: ZYUS) is a life sciences company focused on the development and commercialization of novel cannabinoid-based pharmaceutical drug candidates for pain management. Through rigorous scientific exploration and clinical research, Zyus aims to secure intellectual property protection, safeguarding its innovative therapies and bolstering shareholder value. Zyus's unwavering commitment extends to obtaining regulatory approval of non-opioid-based pharmaceutical solutions, in pursuit of transformational impact on patients' lives.

We seek Safe Harbor.